UCB NORDIC A/S: Financial statements 2023
CVR: 26688949
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
UCB NORDIC A/S (CVR 26688949) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 66,895,000 and a net result of DKK 3,888,000 compared with DKK 4,004,000 the year before. That is an increase of 8.8% compared with the year before. Equity in the 2023 report amounted to DKK 16,106,000. The solvency ratio was 24.4%. The company had 42 employees in the financial year.
- Gross Profit
- DKK 66,895,000
- Profit/Loss
- DKK 3,888,000
- Equity
- DKK 16,106,000
- Total Assets
- DKK 65,918,000
- Employees
- 42
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 66.9M | 3.9M | 16.1M | 42 |
| 2022 | - | 61.5M | 4M | 15.1M | 40 |
| 2021 | - | 60.5M | 3M | 14.1M | 40 |
| 2020 | - | 46.2M | 3.7M | 11.1M | 31 |
| 2019 | - | 39.5M | 3.6M | 10.6M | 26 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
UCB NORDIC A/S has published its annual report for 2022. Gross profit came to DKK 61,499,000, and the net result was DKK 4,004,000.
About UCB NORDIC A/S
UCB NORDIC A/S is a Danish company of the type Aktieselskab based in København S, founded in 2002. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named UCB NORDICS ApS and CELLTECH NORDIC ApS. The management consists of Mari-Ann Retz. The board consists of Laura Ann Byram (chair), Christina Dyreborg Jeppesen and Jaana Mattila. The company is owned by UCB Pharma SA. The company has 48 employees (2026). In 2025, the company reported a gross profit of DKK 88,278,000 and a net result of DKK 6,014,000 compared with DKK 5,226,000 the year before. Equity in the 2025 report amounted to DKK 18,047,000.